• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Consolidated Water, Spectrum Brands, Arco Platform, Semler Scientific And Other Big Stocks Moving Higher On Friday

    8/11/23 11:14:04 AM ET
    $APLS
    $ARCE
    $AVDL
    $BLND
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Other Consumer Services
    Real Estate
    Get the next $APLS alert in real time by email

    U.S. stocks traded mixed, with the Dow Jones gaining around 80 points on Friday. Here are some big stocks recording gains in today’s session.

    Evolv Technologies Holdings, Inc. (NASDAQ:EVLV) shares surged 24.3% to $7.24 after the company reported better-than-expected second-quarter financial results and raised FY23 revenue guidance above estimates.

    Innodata Inc. (NASDAQ:INOD) shares climbed 23.9% to $13.22 after the company posted a narrower quarterly loss.

    IonQ, Inc. (NYSE:IONQ) gained 22% to $17.31 after the company reported second-quarter financial results.

    Groupon, Inc. (NASDAQ:GRPN) gained 20% to $9.12. Goldman Sachs and Credit Suisse raised their price targets on the stock.

    Bitdeer Technologies Group (NASDAQ:BTDR) climbed 19.8% to $ 11.12 following quarterly results.

    Tango Therapeutics, Inc. (NASDAQ:TNGX) rose 18.8% to $7.77. HC Wainwright & Co. maintained Tango Therapeutics with a Buy and raised the price target from $11 to $16.

    Eton Pharmaceuticals, Inc. (NASDAQ:ETON) shares gained 17.9% to $3.0650 after posting upbeat second-quarter results.

    ModivCare Inc. (NASDAQ:MODV) surged 16.6% to $42.31. ModivCare Director Adam Gray acquired a total of 435,893 shares at an average price of $35.74.

    WeWork Inc. (NYSE:WE) shares rose 16.4% to $0.2157 after jumping 43% on Thursday. The stock has been volatile after the company recently said there was substantial doubt over its ability to stay in business.

    Arco Platform Limited (NYSE:ARCE) rose 15.5% to $13.81 after the company announced it signed an agreement to go private at $14 per share in cash.

    Semler Scientific, Inc. (NASDAQ:SMLR) jumped 14.4% to $26.86 after the company reported better-than-expected second-quarter financial results.

    Soho House & Co Inc. (NYSE:SHCO) gained 14.4% to $ 7.00 after the company reported better-than-expected quarterly financial results and updated guidance.

    CleanSpark, Inc. (NASDAQ:CLSK) rose 13.8% to $6.67 after the company reported better-than-expected third-quarter EPS results.

    Consolidated Water Co. Ltd. (NASDAQ:CWCO) gained 13.3% to $23.02. Consolidated Water reported a second-quarter revenue increase of 110% year-over-year to $44.2 million, beating estimates of $30.27 million.

    Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) gained 12.8% to $30.49.

    Pagaya Technologies Ltd. (NASDAQ:PGY) rose 12.5% to $2.6010 after the company reported better-than-expected second-quarter sales results.

    Avadel Pharmaceuticals plc (NASDAQ:AVDL) gained 11.4% to $14.96.

    Erasca, Inc. (NASDAQ:ERAS) surged 11.3% to $2.8950 following second-quarter results.

    Sage Therapeutics, Inc. (NASDAQ:SAGE) rose 11% to $21.50.

    Blend Labs, Inc. (NYSE:BLND) gained 10.5% to $1.58.

    NextNav Inc. (NASDAQ:NN) climbed 10.3% to $4.17 after the company reported second-quarter financial results.

    Similarweb Ltd. (NYSE:SMWB) rose 10.3% to $6.67 following quarterly earnings.

    Granite Ridge Resources, Inc. (NYSE:GRNT) gained 10.3% to $7.82 following upbeat quarterly earnings.

    Despegar.com, Corp. (NYSE:DESP) jumped 9% to $8.84. Morgan Stanley assumed Despegar.com with an Overweight rating.

    First Foundation Inc. (NASDAQ:FFWM) gained 8.8% to $7.85.

    P10, Inc. (NYSE:PX) surged 8.6% to $12.87 following upbeat quarterly results.

    Holley Inc. (NYSE:HLLY) gained 7.4% to $7.98 as the company reported strong earnings for the second quarter and raised its FY23 guidance.

    Spectrum Brands Holdings, Inc. (NYSE:SPB) jumped 6.2% to $79.78 following upbeat quarterly earnings.

    Hawkins, Inc. (NASDAQ:HWKN) jumped 6% to $53.79.

     

    Read More: Top 5 Tech And Telecom Stocks That May Explode This Month

    Get the next $APLS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $APLS
    $ARCE
    $AVDL
    $BLND

    CompanyDatePrice TargetRatingAnalyst
    Tango Therapeutics Inc.
    $TNGX
    4/3/2026$30.00Buy
    Canaccord Genuity
    Tango Therapeutics Inc.
    $TNGX
    4/2/2026$30.00Buy
    Canaccord Genuity
    Apellis Pharmaceuticals Inc.
    $APLS
    3/13/2026$31.00Buy
    Roth Capital
    Tango Therapeutics Inc.
    $TNGX
    2/23/2026$19.00Outperform
    Mizuho
    Similarweb Ltd.
    $SMWB
    2/19/2026Buy → Hold
    Needham
    Similarweb Ltd.
    $SMWB
    2/18/2026$5.00Outperform → Market Perform
    Northland Capital
    Similarweb Ltd.
    $SMWB
    2/18/2026Mkt Outperform → Mkt Perform
    Citizens
    Apellis Pharmaceuticals Inc.
    $APLS
    1/28/2026$24.00Equal Weight
    Barclays
    More analyst ratings

    $APLS
    $ARCE
    $AVDL
    $BLND
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    August 4, 2023 - La FDA aprueba el primer tratamiento oral para la depresión posparto

    For Immediate Release: August 04, 2023 El día de hoy, la Administración de Alimentos y Medicamentos de los Estados Unidos (FDA, por sus siglas en inglés) aprobó Zurzuvae (zuranolona), el primer medicamento oral indicado para tratar la depresión posparto (DPP) en mujeres adultas. La DPP es un episodio depresivo grave que generalmente ocurre después del parto, pero también puede comenzar durante las últimas etapas

    8/8/23 9:34:19 AM ET
    $SAGE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    August 4, 2023 - FDA Approves First Oral Treatment for Postpartum Depression

    For Immediate Release: August 04, 2023 Today, the U.S. Food and Drug Administration approved Zurzuvae (zuranolone), the first oral medication indicated to treat postpartum depression (PPD) in adults. PPD is a major depressive episode that typically occurs after childbirth but can also begin during the later stages of pregnancy. Until now, treatment for PPD was only available as an IV injection given by a health

    8/4/23 6:50:31 PM ET
    $SAGE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for EMPAVELI issued to APELLIS PHARMACEUTICALS INC

    Submission status for APELLIS PHARMACEUTICALS INC's drug EMPAVELI (ORIG-1) with active ingredient PEGCETACOPLAN has changed to 'Approval' on 05/14/2021. Application Category: NDA, Application Number: 215014, Application Classification: Type 1 - New Molecular Entity

    5/17/21 11:09:40 AM ET
    $APLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APLS
    $ARCE
    $AVDL
    $BLND
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Miller Matthew Reade bought $3,389 worth of shares (658 units at $5.15), increasing direct ownership by 0.05% to 1,328,839 units (SEC Form 4)

    4 - Granite Ridge Resources, Inc. (0001928446) (Issuer)

    3/17/26 9:54:33 AM ET
    $GRNT
    Oil & Gas Production
    Energy

    Chief Financial Officer Kettler Ronald Kyle bought $15,510 worth of shares (3,000 units at $5.17), increasing direct ownership by 2% to 123,276 units (SEC Form 4)

    4 - Granite Ridge Resources, Inc. (0001928446) (Issuer)

    3/16/26 10:32:23 AM ET
    $GRNT
    Oil & Gas Production
    Energy

    Director Mccartney John bought $25,800 worth of shares (5,000 units at $5.16), increasing direct ownership by 4% to 136,143 units (SEC Form 4)

    4 - Granite Ridge Resources, Inc. (0001928446) (Issuer)

    3/16/26 10:27:08 AM ET
    $GRNT
    Oil & Gas Production
    Energy

    $APLS
    $ARCE
    $AVDL
    $BLND
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Garner Ebun

    4 - Erasca, Inc. (0001761918) (Issuer)

    4/3/26 9:00:03 AM ET
    $ERAS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Cavaleri Amanda

    4 - CLEANSPARK, INC. (0000827876) (Issuer)

    4/2/26 9:03:02 PM ET
    $CLSK
    Finance: Consumer Services
    Finance

    SEC Form 4 filed by Beynon Roger Paul

    4 - CLEANSPARK, INC. (0000827876) (Issuer)

    4/2/26 9:02:03 PM ET
    $CLSK
    Finance: Consumer Services
    Finance

    $APLS
    $ARCE
    $AVDL
    $BLND
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Biogen to Acquire Apellis, Enhancing the Company's Growth Portfolio in Immunology and Rare Disease, Bolstering Growth Outlook and Accelerating Expansion into Nephrology

    Acquisition will bring two differentiated commercialized immunology medicines to Biogen with EMPAVELI® FDA-approved in three indications, including two rare kidney diseases, and SYFOVRE® FDA-approved in geographic atrophy, an immune-mediated retinal diseaseBringing together Biogen and Apellis' commercialization capabilities will maximize the potential of both EMPAVELI® and SYFOVRE®, while Apellis' talent and expertise will accelerate Biogen's entry into nephrology and augment launch readiness for felzartamab, currently in Phase 3Acquisition is expected to bolster Biogen's near-and long-term growth prospects, adding immediate revenue from two products with significant growth potential; 2025 n

    3/31/26 6:59:00 AM ET
    $APLS
    $BIIB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Bitdeer Engages DCI to Finalise Development of Norway's Largest AI Data Center

    OSLO, Norway, March 30, 2026 (GLOBE NEWSWIRE) -- Bitdeer Technologies Group (NASDAQ:BTDR) ("Bitdeer" or the "Company"), a world-leading technology company for AI and Bitcoin mining infrastructure, today announced its subsidiary, Tydal Data Center AS ("TDC") has entered into an agreement with Data Center Installations AS ("DCI"), a Norwegian data center and critical infrastructure specialized contractor. Under this agreement, DCI will leverage its extensive experience to develop and convert the TDC facility into an artificial intelligence (AI) data center primarily for co-location of the latest Nvidia Vera Rubin AI technology. The project will deliver 180 MW of gross installed capacity wit

    3/30/26 3:00:00 AM ET
    $BTDR
    Finance: Consumer Services
    Finance

    Similarweb Appoints Harel Beit-On as Chairman of its Board of Directors

    Similarweb Ltd. (NYSE:SMWB), a leading digital market intelligence company, today announced the appointment of Harel Beit-On as Chairman of its Board of Directors. Mr. Beit-On has served as a member of Similarweb's Board since 2017 and brings more than 30 years of experience in leadership positions and investment in technology companies. A co-founder and General Partner of the Viola Group, Mr. Beit-On has a strong investment track record as well as a long standing familiarity with Similarweb. Or Offer, Founder and CEO of Similarweb, said, "Harel has been a trusted advisor, mentor, and partner to me and to Similarweb over many years. As AI transforms how decisions are made across every ind

    3/26/26 8:00:00 AM ET
    $SMWB
    Computer Software: Programming Data Processing
    Technology

    $APLS
    $ARCE
    $AVDL
    $BLND
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Canaccord Genuity initiated coverage on Tango Therapeutics with a new price target

    Canaccord Genuity initiated coverage of Tango Therapeutics with a rating of Buy and set a new price target of $30.00

    4/3/26 10:44:59 AM ET
    $TNGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Canaccord Genuity initiated coverage on Tango Therapeutics with a new price target

    Canaccord Genuity initiated coverage of Tango Therapeutics with a rating of Buy and set a new price target of $30.00

    4/2/26 8:13:25 AM ET
    $TNGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Roth Capital initiated coverage on Apellis Pharmaceuticals with a new price target

    Roth Capital initiated coverage of Apellis Pharmaceuticals with a rating of Buy and set a new price target of $31.00

    3/13/26 8:46:55 AM ET
    $APLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APLS
    $ARCE
    $AVDL
    $BLND
    SEC Filings

    View All

    SEC Form SC TO-C filed by Apellis Pharmaceuticals Inc.

    SC TO-C - Apellis Pharmaceuticals, Inc. (0001492422) (Subject)

    4/3/26 5:10:30 PM ET
    $APLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13D/A filed by First Foundation Inc.

    SCHEDULE 13D/A - First Foundation Inc. (0001413837) (Subject)

    4/3/26 4:05:27 PM ET
    $FFWM
    Major Banks
    Finance

    SEC Form EFFECT filed by First Foundation Inc.

    EFFECT - First Foundation Inc. (0001413837) (Filer)

    4/2/26 12:15:09 AM ET
    $FFWM
    Major Banks
    Finance

    $APLS
    $ARCE
    $AVDL
    $BLND
    Leadership Updates

    Live Leadership Updates

    View All

    Similarweb Appoints Harel Beit-On as Chairman of its Board of Directors

    Similarweb Ltd. (NYSE:SMWB), a leading digital market intelligence company, today announced the appointment of Harel Beit-On as Chairman of its Board of Directors. Mr. Beit-On has served as a member of Similarweb's Board since 2017 and brings more than 30 years of experience in leadership positions and investment in technology companies. A co-founder and General Partner of the Viola Group, Mr. Beit-On has a strong investment track record as well as a long standing familiarity with Similarweb. Or Offer, Founder and CEO of Similarweb, said, "Harel has been a trusted advisor, mentor, and partner to me and to Similarweb over many years. As AI transforms how decisions are made across every ind

    3/26/26 8:00:00 AM ET
    $SMWB
    Computer Software: Programming Data Processing
    Technology

    Groupon Launches Board-Level Artificial Intelligence Committee and Appoints Amit Shah to Board of Directors

    Technology executive and AI entrepreneur to chair new committee as Company positions marketplace for the era of agentic commerceChicago, Illinois--(Newsfile Corp. - March 10, 2026) - Groupon, Inc. (NASDAQ:GRPN) today announced the appointment of Amit Shah to its Board of Directors, effective March 10, 2026, and the formation of a dedicated Artificial Intelligence Committee of the Board. Shah, a seasoned technology executive and AI entrepreneur, will serve as the Committee's inaugural Chair.With this action, Groupon becomes one of the first publicly traded consumer marketplaces to establish a board-level committee dedicated to artificial intelligence. The formation of the Committee reflects t

    3/10/26 4:15:00 PM ET
    $APRN
    $FLWS
    $GRPN
    Catalog/Specialty Distribution
    Consumer Discretionary
    Other Specialty Stores
    Advertising

    Tango Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Highlights

    Initial Phase 1/2 trial data of vopimetostat in combination with Revolution Medicines' RAS(ON) inhibitors in MTAP-deleted pancreatic cancer in 2026 with continued robust patient enrollment New clinical supply agreement with Erasca, plus ongoing Revolution Medicines collaboration, supports potential of vopimetostat as the preferred PRMT5 inhibitor for combination with RAS targeted therapies in oncology Cash position of $343 million as of December 31, 2025, with runway into 2028 beyond anticipated key data inflection points BOSTON, March 05, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ:TNGX), a clinical-stage biotechnology company committed to discovering and delivering the n

    3/5/26 7:00:00 AM ET
    $TNGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APLS
    $ARCE
    $AVDL
    $BLND
    Financials

    Live finance-specific insights

    View All

    Biogen to Acquire Apellis, Enhancing the Company's Growth Portfolio in Immunology and Rare Disease, Bolstering Growth Outlook and Accelerating Expansion into Nephrology

    Acquisition will bring two differentiated commercialized immunology medicines to Biogen with EMPAVELI® FDA-approved in three indications, including two rare kidney diseases, and SYFOVRE® FDA-approved in geographic atrophy, an immune-mediated retinal diseaseBringing together Biogen and Apellis' commercialization capabilities will maximize the potential of both EMPAVELI® and SYFOVRE®, while Apellis' talent and expertise will accelerate Biogen's entry into nephrology and augment launch readiness for felzartamab, currently in Phase 3Acquisition is expected to bolster Biogen's near-and long-term growth prospects, adding immediate revenue from two products with significant growth potential; 2025 n

    3/31/26 6:59:00 AM ET
    $APLS
    $BIIB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Bitdeer Engages DCI to Finalise Development of Norway's Largest AI Data Center

    OSLO, Norway, March 30, 2026 (GLOBE NEWSWIRE) -- Bitdeer Technologies Group (NASDAQ:BTDR) ("Bitdeer" or the "Company"), a world-leading technology company for AI and Bitcoin mining infrastructure, today announced its subsidiary, Tydal Data Center AS ("TDC") has entered into an agreement with Data Center Installations AS ("DCI"), a Norwegian data center and critical infrastructure specialized contractor. Under this agreement, DCI will leverage its extensive experience to develop and convert the TDC facility into an artificial intelligence (AI) data center primarily for co-location of the latest Nvidia Vera Rubin AI technology. The project will deliver 180 MW of gross installed capacity wit

    3/30/26 3:00:00 AM ET
    $BTDR
    Finance: Consumer Services
    Finance

    Holley Performance Brands Acquires HRX, Expanding Safety & Racing Portfolio

    NASHVILLE, Tenn., March 20, 2026 (GLOBE NEWSWIRE) -- Holley Performance Brands (NYSE:HLLY), a leader in automotive aftermarket performance solutions, today announced it has acquired HRX, an Italian motorsports racewear brand serving drivers and teams across karting and competitive racing categories. The terms of the transaction were not disclosed. HRX has established a presence across European racing circuits and select international markets, focusing on technical racewear, customization and customer relationships within the motorsports community. The acquisition adds complementary racewear capabilities to Holley's Safety & Racing portfolio and expands the company's presence in European

    3/20/26 8:30:00 AM ET
    $HLLY
    Auto Parts:O.E.M.
    Consumer Discretionary

    $APLS
    $ARCE
    $AVDL
    $BLND
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by ModivCare Inc.

    SC 13D/A - ModivCare Inc (0001220754) (Subject)

    12/13/24 9:05:42 PM ET
    $MODV
    Transportation Services
    Consumer Discretionary

    Amendment: SEC Form SC 13D/A filed by P10 Inc.

    SC 13D/A - P10, Inc. (0001841968) (Subject)

    12/13/24 9:00:20 PM ET
    $PX
    Investment Managers
    Finance

    Amendment: SEC Form SC 13D/A filed by ModivCare Inc.

    SC 13D/A - ModivCare Inc (0001220754) (Subject)

    12/13/24 5:07:48 PM ET
    $MODV
    Transportation Services
    Consumer Discretionary